Pictet Asset Management Holding SA Has $21.88 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 972,293 shares of the company’s stock after acquiring an additional 135,969 shares during the period. Pictet Asset Management Holding SA owned 1.99% of Enliven Therapeutics worth $21,877,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Enliven Therapeutics by 295.8% during the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after buying an additional 42,012 shares during the period. Geode Capital Management LLC boosted its position in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after acquiring an additional 67,813 shares during the last quarter. Patient Square Capital LP acquired a new stake in Enliven Therapeutics during the 3rd quarter worth about $2,313,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics by 10.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock valued at $668,000 after purchasing an additional 2,944 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 1,000 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the transaction, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $325,520. The trade was a 7.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now owns 990,392 shares in the company, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 72,784 shares of company stock valued at $1,607,736. 29.20% of the stock is owned by insiders.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $19.68 on Tuesday. Enliven Therapeutics, Inc. has a 52-week low of $15.96 and a 52-week high of $30.03. The business’s 50 day simple moving average is $21.24 and its two-hundred day simple moving average is $23.72. The firm has a market cap of $964.40 million, a P/E ratio of -10.36 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ELVN shares. HC Wainwright boosted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st. BTIG Research began coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Buy” and an average target price of $38.75.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.